Clinical trial / 2021
In mild to moderate Alzheimer's disease, 52 weeks of trans-resveratrol decreased CSF MMP-9 by 46% and reduced brain volume compared to placebo.
Thirty patients with moderate to mild Alzheimer's disease were randomized to receive 500 mg trans-resveratrol orally once daily or placebo for 52 weeks. Trans-resveratrol did not lead to statistically significant changes in blood or CSF Aβ40, whereas placebo participants showed significant decreases in CSF (P = 0.024) and plasma Aβ40 (P = 0.036). Compared with placebo, trans-resveratrol resulted in a significant reduction in brain volume at 52 weeks (P = 0.011) and a 46% decrease in CSF matrix metallopeptidase 9 (P = 0.033).
- Study type
- Randomized, double-blind, placebo-controlled trial
- Who was studied
- 30 patients with mild to moderate Alzheimer's disease
- What was measured
- Plasma/CSF Aβ40 and Aβ42, brain MRI volume, and CSF MMP-9 levels
THE PAPER
Neuroprotective Effect of Trans-Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial.
Gu J, Li Z, Chen H, Xu X, Li Y, Gui Y. Neurol Ther, 2021.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.